ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Complement C5

Complement C5

概要

Name:Complement C5
Target Synonym:C5a,Complement Component 5,ECLZB,Anaphylatoxin C5a Analog,C5a Anaphylatoxin,C5b,C5,Prepro-C5,CPAMD4,Complement C5,C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4,C5D
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:18
Lastest Research Phase:Approved

Product Inquiry

* We couldn't find what you're looking for. You can let us help by filling the form below. Our tech team will get back to you shortly.
* This form is only used to collect product demand consultation. All the information will be kept strictly confidential.
Product inquiry collection form
*
*
*
*
*
*
*
*
*
ACRO Quality

生物活性データの一部

CO5-H82E9-ELISA
 Complement C5 ELISA

Immobilized Biotinylated Human Complement C5, His,Avitag (Cat. No. CO5-H82E9) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-Human C5a Human Antibody, Human IgG1 with a linear range of 0.1-3 ng/mL (QC tested).

CO5-H52Ha-MALS-HPLC
Complement C5 MALS images

The purity of Human Complement C5, His Tag (Cat. No. CO5-H52Ha) is more than 85% and the molecular weight of this protein is around 180-220 kDa verified by SEC-MALS.

Synonym Name

Complement C5,C5,CPAMD4

Background

Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with C5AR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Eculizumab 5G1-1; HAL-1; LEX-98; h-5G1.1 Approved Alexion Pharmaceuticals Inc Soliris Mainland China Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal Alexion Europe Sas 2007-03-16 Neuromyelitis Optica; Macular Degeneration; Diabetes Mellitus; Kidney Failure, Chronic; Thrombocytopenia; Guillain-Barre Syndrome; Urea Cycle Disorders, Inborn; Asthma; Nasopharyngeal Carcinoma; Glomerulonephritis, Membranoproliferative; Pre-Eclampsia; Anemia, Hemolytic, Autoimmune; Myasthenia Gravis; Infant, Newborn, Diseases; Antiphospholipid Syndrome; Delayed Graft Function; Atypical Hemolytic Uremic Syndrome; Rejection of organ transplantation; Vagus Nerve Diseases; Hemoglobinuria, Paroxysmal; End Stage Liver Disease; Rejection of renal transplantation; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; HELLP Syndrome Details
Ravulizumab ALXN-1810; ALXN-1210 Approved Alexion Pharmaceuticals Inc, Xencor Inc Ultomiris EU Myasthenia Gravis Alexion Europe Sas 2018-12-21 Myasthenia Gravis; Dermatomyositis; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Thrombotic Microangiopathies; Lupus Nephritis; Atypical Hemolytic Uremic Syndrome; Acute Kidney Injury; Neuromyelitis Optica; Pneumonia, Viral; Amyotrophic Lateral Sclerosis; Acute Lung Injury Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
ALXN-5500 ALXN-5500 Phase 1 Clinical Alexion Pharmaceuticals Inc Hemoglobinuria, Paroxysmal Details
Eculizumab biosimilar (CinnaGen) Phase 3 Clinical Cinnagen Hemoglobinuria, Paroxysmal Details
Eculizumab biosimilar (IBC GENERIUM) Phase 3 Clinical Ibc Generium Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome Details
Vilobelimab CaCP-29; IFX-1 Phase 3 Clinical Inflarx Nv Shock, Septic; Granulomatosis with Polyangiitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Drug-Related Side Effects and Adverse Reactions; Microscopic Polyangiitis; Pyoderma Gangrenosum; Sepsis; Coronavirus Disease 2019 (COVID-19); Lung Diseases, Interstitial; Hidradenitis Suppurativa; Systemic Inflammatory Response Syndrome Details
Eculizumab biosimilar (Amgen) ABP-959 Phase 3 Clinical Amgen Inc Hemoglobinuria, Paroxysmal Details
IM-101 IM-101 Phase 1 Clinical ImmunAbs Inc Autoimmune Diseases Details
Zilucoplan RA-101495-SC; RA-101495 Phase 3 Clinical Ucb Sa, Ra Pharma Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Muscular Diseases Details
Nomacopan EV-576; rVA576; rEV-576 Phase 3 Clinical Evolutec Hemoglobinuria, Paroxysmal; Thrombotic Microangiopathies; Pemphigoid, Bullous; Keratoconjunctivitis Details
STSA-1002 STSA1002; STSA-1002 Phase 1 Clinical Staidson(Beijing) Biopharmaceuticals Co Ltd Coronavirus Disease 2019 (COVID-19) Details
Eculizumab biosimilar (Biocad) BCD-148 Phase 3 Clinical Biocad Hemoglobinuria, Paroxysmal Details
Avacincaptad pegol ARC-187; ARC-1905 Phase 3 Clinical Archemix Corp Geographic Atrophy; Stargardt Disease; Macular Degeneration Details
Gefurulimab TPP-2511; ALXN-1720; CON-9978 Phase 3 Clinical Alexion Pharmaceuticals Inc Myasthenia Gravis; Proteinuria Details
P-014 P014; KP-104 Phase 2 Clinical Kira Pharmaceuticals LLC Hemoglobinuria, Paroxysmal; Lupus Erythematosus, Systemic; Glomerulonephritis Details
Pozelimab REGN-3918 Phase 3 Clinical Regeneron Pharmaceuticals Inc Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Protein-Losing Enteropathies Details
Cemdisiran ALN-62643; ALN-CC5; AD-62643 Phase 3 Clinical Alnylam Pharmaceuticals Inc Myasthenia Gravis; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome Details
eculizumab biosimilar(Isu Abxis) ISU-305 Phase 1 Clinical Isu Abxis Co Ltd Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome Details
Eculizumab biosimilar (Samsung Bioepis) SB-12 Phase 3 Clinical Samsung Bioepis Co Ltd Hemoglobinuria, Paroxysmal Details
CAN-106 CAN-106 Phase 2 Clinical Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd Hemoglobinuria, Paroxysmal; Genetic Diseases, Inborn Details
BDB-001 BDB-001; BDB001; BDB 001; BDB-1 Phase 3 Clinical Staidson(Beijing) Biopharmaceuticals Co Ltd Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Solid tumours; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa Details

This web search service is supported by Google Inc.

totopphone